These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 1462276)

  • 21. Immune status in Crohn's disease. V. Decreased in vitro natural killer cell activity in peripheral blood.
    Auer IO; Ziemer E; Sommer H
    Clin Exp Immunol; 1980 Oct; 42(1):41-9. PubMed ID: 7460390
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The association of functional catechol-O-methyltransferase haplotypes with risk of Parkinson's disease, levodopa treatment response, and complications.
    Bialecka M; Kurzawski M; Klodowska-Duda G; Opala G; Tan EK; Drozdzik M
    Pharmacogenet Genomics; 2008 Sep; 18(9):815-21. PubMed ID: 18698234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The validity of the GaitRite and the Functional Ambulation Performance scoring system in the analysis of Parkinson gait.
    Nelson AJ; Zwick D; Brody S; Doran C; Pulver L; Rooz G; Sadownick M; Nelson R; Rothman J
    NeuroRehabilitation; 2002; 17(3):255-62. PubMed ID: 12237507
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Circulating interleukin-15 and RANTES chemokine in Parkinson's disease.
    Rentzos M; Nikolaou C; Andreadou E; Paraskevas GP; Rombos A; Zoga M; Tsoutsou A; Boufidou F; Kapaki E; Vassilopoulos D
    Acta Neurol Scand; 2007 Dec; 116(6):374-9. PubMed ID: 17986095
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease.
    Mouradian MM; Heuser IJ; Baronti F; Chase TN
    Ann Neurol; 1990 Jan; 27(1):18-23. PubMed ID: 2301923
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
    Huot P; Lévesque M; Parent A
    Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia.
    Sian J; Dexter DT; Lees AJ; Daniel S; Agid Y; Javoy-Agid F; Jenner P; Marsden CD
    Ann Neurol; 1994 Sep; 36(3):348-55. PubMed ID: 8080242
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Rasagiline in daily clinical use. Results of a treatment study of Parkinson patients with a combination treatment].
    Jost WH; Klasser M; Reichmann H
    Fortschr Neurol Psychiatr; 2008 Oct; 76(10):594-9. PubMed ID: 18833504
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Natural killer cell activity in multiple sclerosis patients].
    Pál E; Varjú G; Vécsei L; Szekeres J; Pálffy G
    Orv Hetil; 1997 Dec; 138(50):3167-70. PubMed ID: 9446081
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Peripheral blood markers of oxidative stress in Parkinson's disease.
    Younes-Mhenni S; Frih-Ayed M; Kerkeni A; Bost M; Chazot G
    Eur Neurol; 2007; 58(2):78-83. PubMed ID: 17565220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Evaluation of effectiveness of the micrographia's therapy in Parkinson's disease patients].
    Jarzebska E
    Pol Merkur Lekarski; 2006 Jun; 20(120):688-90. PubMed ID: 17007269
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of nigral stimulation on locomotion and postural stability in patients with Parkinson's disease.
    Chastan N; Westby GW; Yelnik J; Bardinet E; Do MC; Agid Y; Welter ML
    Brain; 2009 Jan; 132(Pt 1):172-84. PubMed ID: 19001482
    [TBL] [Abstract][Full Text] [Related]  

  • 33. L-dihydroxyphenylalanine and complex I deficiency in Parkinson's disease brain.
    Cooper JM; Daniel SE; Marsden CD; Schapira AH
    Mov Disord; 1995 May; 10(3):295-7. PubMed ID: 7651446
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Levodopa treatment does not affect low-dose apomorphine test in patients with Parkinson's disease.
    Happe S; Tings T; Helmschmied K; Neubert K; Wuttke W; Paulus W; Trenkwalder C
    Mov Disord; 2004 Dec; 19(12):1511-5. PubMed ID: 15390061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prognostic significance of circulating cytotoxic lymphocytes against autologous tumors in patients with bladder cancer.
    Mizutani Y; Okada Y; Terachi T; Yoshida O
    J Urol; 1996 Mar; 155(3):888-92; discussion 892-4. PubMed ID: 8583600
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Association of leukocytosis with amphetamine and cocaine use.
    Richards JR; Farias VF; Clingan CS
    ScientificWorldJournal; 2014; 2014():207651. PubMed ID: 24578625
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Relationship between the immune system and the diseases of the central nervous system.
    Bokor M; Faragó A; Schnabel R; Garam T
    Ther Hung; 1992; 40(2):51-7. PubMed ID: 1462276
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The immunological status in Parkinson's disease.
    Fiszer U; Piotrowska K; Korlak J; Członkowska A
    Med Lab Sci; 1991 Jul; 48(3):196-200. PubMed ID: 1787777
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antibody-dependent cell-mediated cytotoxicity (ADCC) in Parkinson's disease.
    Bokor M; Faragó A; Garam T; Malatinszky G; Schnabel R
    J Neurol Sci; 1993 Mar; 115(1):47-50. PubMed ID: 8468591
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Natural killer cells of Parkinson's disease patients are set up for activation: a possible role for innate immunity in the pathogenesis of this disease.
    Mihara T; Nakashima M; Kuroiwa A; Akitake Y; Ono K; Hosokawa M; Yamada T; Takahashi M
    Parkinsonism Relat Disord; 2008; 14(1):46-51. PubMed ID: 17702627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.